Table1_Impact of early heparin therapy on mortality in critically ill patients with sepsis associated acute kidney injury: a retrospective study from the MIMIC-IV database.DOCX

Background: Inflammatory-coagulation dysfunction plays an increasingly important role in sepsis associated acute kidney injury (SAKI). This study aimed to investigate whether early heparin therapy improves survival in patients with SAKI.Methods: Patients with SAKI were identified from the Medical Information Mart for Intensive Care-IV database. The patients were divided into two groups: those who received heparin subcutaneously within 48 h after intensive care unit (ICU) admission and the control group, who received no heparin. The primary endpoint was ICU mortality, the secondary outcomes were 7-day, 14-day, 28-day, and hospital mortality. Propensity score matching (PSM), marginal structural Cox model (MSCM), and E-value analyses were performed.Results: The study included 5623 individuals with SAKI, 2410 of whom received heparin and 3213 of whom did not. There were significant effects on ICU and 28-day mortality in the overall population with PSM. MSCM further reinforces the efficacy of heparin administration reduces ICU mortality in the general population. Stratification analysis with MSCM showed that heparin administration was associated with decreased ICU mortality at various AKI stages. Heparin use was also associated with reduced 28-day mortality in patients with only female, age >60 years, and AKI stage 3, with HRs of 0.79, 0.77, and 0.60, respectively (p Conclusion: Early heparin therapy for patients with SAKI decreased ICU mortality. Further analysis demonstrated that heparin therapy was associated with reduced 28-day mortality rate in patients only among female, age > 60 years and AKI stage 3.</p

Overall survival (OS) in EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients in a matched case-control analysis.

<p>Overall survival (OS) in EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients in a matched case-control analysis.</p

Typical distributions of BAFF and BAFF-R expression in follicular lymphoma (FL) and representative cases with different immunostaining intensity for BAFF and BAFF-R.

<p>(A) Distribution of BAFF expression in tumor specimen of FL. (B) Distribution of BAFF-R expression in tumor specimen of FL. (C) Negative staining (−) for BAFF. (D) Weak staining (1+) for BAFF. (E) Moderate staining (2+) for BAFF. (F) Strong staining (3+) for BAFF. (G) Negative staining (−) for BAFF-R. (H) Weak staining (1+) for BAFF-R. (I) Moderate staining (2+) for BAFF-R. (J) Strong staining (3+) for BAFF-R.</p

Clinical features and survival outcomes of 16 EBV-positive elderly DLBCL patients.

<p>M, male; F, female; LN, lymph node; IPI, International Prognostic Index; R, Rituximab; CHOP, cyclophosphamide, doxorubicin(may be substituted by epirubicin or peglyated liposome doxorubicin), vincristine,prednisone; EPOCH, etoposide, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; AWD, alive with disease; AND, alive with no evidence of disease; DOD, died of disease.</p><p>Clinical features and survival outcomes of 16 EBV-positive elderly DLBCL patients.</p

Progression-free survival (PFS) and Overall survival (OS) for all 115 patients with follicular lymphoma according to the prognostic scoring system incorporating the 3 independent risk factors for both PFS and OS.

<p>(A) Increasing scores correlated with inferior PFS (<i>P</i><0.001). (B) Increasing scores correlated with inferior OS (<i>P</i><0.001). LR, low risk group (patients with no risk factor); IR, intermediate risk group (patients with 1 risk factor); HR, high risk group (patients with 2–3 risk factors).</p

Correlation between main clinical features of 115 patients with FL and expression of BAFF and BAFF-R.

<p>FL, follicular lymphoma; BAFF, B-cell activation factor; BAFF-R, B-cell activation factor receptor; ECOG PS, Easter Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin; FLIPI, Follicular Lymphoma International Prognostic Index.</p

Prognostic value of risk factors for 115 patients with FL in multivariate analysis.

<p>FL, follicular lymphoma; PFS, Progression-free survival; OS, Overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; −, not applicable; BM, bone marrow; LDH, lactate dehydrogenase; FLIPI, Follicular Lymphoma International Prognostic Index; H, high; I, intermediate; L, low; BAFF-R, B-cell activation factor receptor.</p

Progression-free survival (PFS) and overall survival (OS) for 115 patients with follicular lymphoma according to BAFF and BAFF-R expression levels.

<p>(A) No significant difference in PFS was noted between low- and high-BAFF expression groups (<i>P</i> = 0.929). (B) No significant difference in OS was noted between low- and high-BAFF expression groups (<i>P</i> = 0.647). (C) Patients with high-BAFF-R expression showed significant inferior PFS (<i>P</i> = 0.013). (D) Patients with high-BAFF-R expression showed significant inferior OS (<i>P</i> = 0.03).</p

Progression-free survival (PFS) and overall survival (OS) for 64 patients with follicular lymphoma treated with non-rituximab regimens according to BAFF and BAFF-R expression levels.

<p>(A) No significant difference in PFS was noted between low- and high-BAFF expression groups (<i>P</i> = 0.96). (B) No significant difference in OS was noted between low- and high-BAFF expression groups (<i>P</i> = 0.768). (C) Patients with high-BAFF-R expression showed significant inferior PFS (<i>P</i> = 0.028). (D) Patients with high-BAFF-R expression showed significant inferior OS (<i>P</i> = 0.044).</p

Treatment responses and survival outcomes of EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients.

<p>CR, complete remission; PFS, progression free survival; OS, overall survival.</p><p>Treatment responses and survival outcomes of EBV-positive (study group) and EBV-negative (control group) elderly DLBCL patients.</p